BioCryst Pharmaceuticals (NASDAQ:BCRX) launches a Phase 1 clinical trial evaluating single and multiple ascending doses of BCX9250, an oral activin receptor-like kinase-2 (ALK-2) inhibitor, in healthy volunteers. Results should be available in H2 2020.
The company is developing the candidate for the treatment of a rare inherited disorder called fibrodysplasia ossificans progressiva in which muscle and connective tissue are gradually replaced by bone resulting in restricted movement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.